Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Kansas City, Kansas 66205


Purpose:

The purpose of this study is to determine if high dose supplementation with the omega-3 fatty acids EPA and DHA, when added to a weight loss program, is well tolerated in the study population and if there is an increase in the favorable change in blood and tissue breast cancer risk factors when compared to weight loss alone.


Criteria:

Inclusion Criteria: - Evidence of Hyperplasia with Masood score of 13 or higher and 500 or more epithelial cells on cytology slide of screening Random Periareolar Fine Needle Aspiration (RPFNA) - Access to smart phone and or computer - Willing to comply with diet, exercise and lifestyle modification during weight reduction and maintenance phase. - Willing to start the dietary and exercise intervention within 9 months of RPFNA - Willing to complete quality of life questionnaires at multiple visits - Willing to have a medical history and physical at multiple visits - Willing to have an additional RPFNA at two additional visits - Be willing to have blood drawn at multiple visits - Willing to sign and able to understand consent for the RPFNA's and study participation - Reasonable hematopoetic, kidney and liver function consistent with safe participation on this trial. Exclusion Criteria: - Having taken medications that seriously affect metabolism such as steroids, dexatrim or other diet drugs within 3 weeks of study registration - Have changed dose or type of hormone supplementation within 3 months - Currently receiving other investigational agents - Have been on a chemoprevention trial within 6 months or taken a Selective Estrogen Receptor Modulator or aromatase inhibitor within last 6 months. - Need for chronic use of aspirin, nonsteroidal anti-inflamatory drug (NSAID) or other anti-inflammatory agents - Taking metformin, or other diabetes medications - Taking statins - Unable to participate in moderate intensity exercise (walking, treadmill, elliptical, water aerobics) - Would be unable to participate, by phone, in weekly phone call sessions - Cells suspicious for malignancy as assessed by cytotechnologist or cytopathologist.


NCT ID:

NCT02101970


Primary Contact:

Principal Investigator
Carol J. Fabian, M.D.
University of Kansas Medical Center


Backup Contact:

N/A


Location Contact:

Kansas City, Kansas 66205
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.